That is the question considered by Wouters and Kuha (2024) in a recent Health Affairs article. The authors use IQVIA data between 1982 and 2024 on the timing of drug launches and estimate median delay times using a Kaplan Meier estimates. They find that:
From the first launch globally, the median time to availability was 2.7 years for high-income countries, 4.5 years for upper-middle-income countries, 6.9 years for lower-middle-income countries, and 8.0 years for low-income countries. The gap between richer (high- and upper-middle-income) and poorer (lower-middle- and low-income) countries remained largely unchanged over time.
Moreover, the authors also find that about three-quarters (74%) of first launches occurred in eight countries with most first launches occurring (in order) in: US, Netherlands, Sweden, Switzerland, UK, France, Germany, and Japan.
You can read the full article here.
Disclaimer :
This article is solely for informational purposes, any medical information contained is not a substitute for professional medical advice and readers should not rely on it as such.
If you believe there may be errors or misinformation in this article, we encourage you to contact the webmasters by messaging the provided contact information.
Your feedback is valuable, and we are committed to rectifying any inaccuracies. Please note that the content will be re-evaluated, and corrections will be made as necessary following your submission.